An experimental daily weight loss pill has demonstrated promising results, enabling trial participants to reduce their body weight by over 10 per cent within a six-month period.
Separately, research suggests that elecoglipron, developed by AstraZeneca, also holds promise for improving blood sugar levels in individuals living with type 2 diabetes.
